Skip to main content
. 2003 Apr 25;138(8):1562–1570. doi: 10.1038/sj.bjp.0705214

Figure 6.

Figure 6

The tyrosine kinase inhibitor, herbimycin A, inhibits the sustained vasodilatation by flow, but it does not change acetylcholine vasodilatation. Area under the vasodilatation curve (AUC) for (a, c) flow and (b, d) acetylcholine in the absence or the presence of a tyrosine kinase (c-SRC) inhibitor, herbimycin A (1 μM). The experiments were performed in (a, b) the presence of indomethacin (3 μM) and (c, d) the presence of indomethacin and ADMA (1 mM). Results are mean±s.e.m. of seven to nine preparations. Differences in responses evaluated by two-way analysis of variance: *P<0.05 versus responses obtained in the presence of indomethacin.